Issue | Pharma's Almanac

Current Issue: Q2 2016

Innovative & Expert Partners

Also In This Issue

Bioavailability: What Are Your Thoughts On Enhancing Bioavailability With Novel Technologies?

Franck Pavan, CDMO Department Manager, Injection products, Pierre Fabre A: From my perspective, new enhancing bioavailability technologies will move forward in the future. Most of the new active ingredients that are discovered have physical and chemical characteristics that are not compliant with, let’s say, a clear solubility in water and that’s why it’s more and […]

Innovation at the Heart of Biopharmaceutical Industry Growth

Nice Insight Highlights Key Trends Driving Growth in the Biopharmaceutical Market The global biopharmaceuticals market was valued at $162 billion in 2014 and predicted by Persistence Market Research to grow at a compound annual growth rate of 9.4% from 2014 to 2020 to reach $278 billion.1 This healthy growth rate is attributed to the increasing prevalence […]

Dose and Form Matter: Future of Care Demands Optimal Drug Delivery

Contract manufacturers, the pharma industry they support and the healthcare community are working hard to address medication non-adherence and improve patient outcomes; but more can be done to ensure innovative medicines achieve their full potential. It’s well established that children, seniors and even cogent, non-impaired adults are prone to use their prescribed medications incorrectly. Medication […]

Establishing Specialized CDMO Capabilities for the Production of Advanced Therapies

Most pharmaceutical and biopharmaceutical companies  are establishing closer relationships with a few select service providers that have unique combinations of capabilities  and demonstrated performance. To be successful, contract development and manufacturing organizations (CDMOs) must be forward thinking — constantly anticipating the future needs of potential customers and investing in state-of-the-art facilities, equipment and technologies. To […]

Luca Mantovani, CEO, INFA Group A: DEFINITELY, YES. Imagine that 10 years ago, even 5 years ago, there was a lot of discussion about biosimilars but there was not really a successful breakthrough. I expect that now biosimilars will gain, in the next 5-10 years, strong traction and I see several companies which are jumping […]

Single-Use Equipment Proving Useful Managing Biomanufacturing Costs

Single-use technologies improve flexibility and are introducing a new era in operational economy for bioprocessors. Biopharmaceuticals continue to grow in importance and number as pharmaceutical research uncovers new treatment options for new and existing conditions. Growth in emerging economies with improved living standards and a rapidly growing middle class is also helping to fuel this […]

From Qualified to Ideal: The Importance of Partnership

Nice Insight’s virtual panelists weigh in on what makes contract service relationships work best. Outsourcing is often critical to the success of a product and partnership can be just as critical to the success of an outsourcing relationship. According to the 2016 Nice Insight CDMO Outsourcing Survey, nearly 70% of outsourcing projects were sent to […]

Rigorous Integration in a Scalable Development and Manufacturing Enterprise to Support Continued Growth of Biopharmaceuticals

The pharmaceutical and biopharmaceutical development and manufacturing market continue to experience significant expansion as the development of small molecule drugs and more complex large-molecule biologics rival for attention. Small and midsize pharma/biotech companies are leading drug discovery and the engagement of contract development and manufacturing organizations (CDMOs) helps them to improve capabilities and enable companies […]

Research Database Recommendations

As the pharmaceutical industry grows, the research surrounding it follows suit. To stay ahead of industry trends and keep abreast of the myriad changes in drug development, including approvals and expirations, it is recommended that a contract development manufacturing organization (CDMO) or contract research organization (CRO) subscribe to one or many of the following databases, […]

Past Issues

View all Past Issues

The Cutting-Edge Therapies Issue

View Issue »

Issue #2 | Volume #7 | Q2 2022

The Next-Generation Therapies Issue

View Issue »

Issue #1 | Volume #7 | Q1 2022

Clinical Services, Contract Development & Manufacturing

View Issue »

Issue #1 | Volume #2 | Q1 2016

The Outsourcing Issue

View Issue »

Issue #3 | Volume #6 | Q3 2020